PET/CT response criteria (European Organization for Research and Treatment of Cancer) predict survival better than response evaluation criteria in solid tumors in locally advanced cervical cancer treated with chemoradiation

Jung Won Yoon, Sunghoon Kim, Sang Wun Kim, YoungTae Kim, Won Jun Kang, Eun Ji Nam

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose To investigate whether the ratio of SUVs measured with 18F-FDG PET/CT between pretreatment and posttreatment has prognostic value in patients with locally advanced cervical cancer treated with primary chemoradiation therapy. Methods Cases of locally advanced cervical cancer (International Federation of Gynecology and Obstetrics stages IB1 to IVA) treated with a nonsurgical curative modality (172 cases including chemoradiation or radiation therapy) were reviewed. 18F-FDG PET/CT parameters, including SUVmax and SUVmean, were evaluated by 18F-FDG PET/CT performed prior to treatment and 6 weeks after the end of treatment. Metabolic response was evaluated according to the European Organization for Research and Treatment of Cancer guidelines and was compared with radiologic response measured according to the Response Evaluation Criteria In Solid Tumours (RECIST). Results In total, 142 patients receiving chemoradiation showed radiologic responses (median 56% decrease in maximal diameter), whereas 160 and 146 patients showed metabolic responses measured with SUVmax and SUVmean, respectively (73% decrease in SUVmax; 48% decrease in SUVmean). Radiologic response and metabolic response were significantly correlated for SUVmax and SUVmean (P = 0.0009; P = 0.0457, respectively). Kaplan-Meier analysis revealed significant differences in overall survival and progression-free survival between the responder and nonresponder groups, based on the European Organization for Research and Treatment of Cancer criteria (both P < 0.001), whereas no significant difference was found when using RECIST criteria (P = 0.058, P = 0.088, respectively). Conclusions 18F-FDG PET/CT parameters are good prognostic markers for the response of cervical cancer patients to concurrent chemoradiation therapy, as compared with the RECIST criteria.

Original languageEnglish
Pages (from-to)677-682
Number of pages6
JournalClinical Nuclear Medicine
Volume41
Issue number9
DOIs
Publication statusPublished - 2016 Sep 1

Fingerprint

Uterine Cervical Neoplasms
Fluorodeoxyglucose F18
Survival
Research
Neoplasms
Therapeutics
Kaplan-Meier Estimate
Gynecology
Obstetrics
Disease-Free Survival
Response Evaluation Criteria in Solid Tumors
Radiotherapy
Guidelines

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

@article{1a1fca286e84400a8e832dfecffcba96,
title = "PET/CT response criteria (European Organization for Research and Treatment of Cancer) predict survival better than response evaluation criteria in solid tumors in locally advanced cervical cancer treated with chemoradiation",
abstract = "Purpose To investigate whether the ratio of SUVs measured with 18F-FDG PET/CT between pretreatment and posttreatment has prognostic value in patients with locally advanced cervical cancer treated with primary chemoradiation therapy. Methods Cases of locally advanced cervical cancer (International Federation of Gynecology and Obstetrics stages IB1 to IVA) treated with a nonsurgical curative modality (172 cases including chemoradiation or radiation therapy) were reviewed. 18F-FDG PET/CT parameters, including SUVmax and SUVmean, were evaluated by 18F-FDG PET/CT performed prior to treatment and 6 weeks after the end of treatment. Metabolic response was evaluated according to the European Organization for Research and Treatment of Cancer guidelines and was compared with radiologic response measured according to the Response Evaluation Criteria In Solid Tumours (RECIST). Results In total, 142 patients receiving chemoradiation showed radiologic responses (median 56{\%} decrease in maximal diameter), whereas 160 and 146 patients showed metabolic responses measured with SUVmax and SUVmean, respectively (73{\%} decrease in SUVmax; 48{\%} decrease in SUVmean). Radiologic response and metabolic response were significantly correlated for SUVmax and SUVmean (P = 0.0009; P = 0.0457, respectively). Kaplan-Meier analysis revealed significant differences in overall survival and progression-free survival between the responder and nonresponder groups, based on the European Organization for Research and Treatment of Cancer criteria (both P < 0.001), whereas no significant difference was found when using RECIST criteria (P = 0.058, P = 0.088, respectively). Conclusions 18F-FDG PET/CT parameters are good prognostic markers for the response of cervical cancer patients to concurrent chemoradiation therapy, as compared with the RECIST criteria.",
author = "Yoon, {Jung Won} and Sunghoon Kim and Kim, {Sang Wun} and YoungTae Kim and Kang, {Won Jun} and Nam, {Eun Ji}",
year = "2016",
month = "9",
day = "1",
doi = "10.1097/RLU.0000000000001269",
language = "English",
volume = "41",
pages = "677--682",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - PET/CT response criteria (European Organization for Research and Treatment of Cancer) predict survival better than response evaluation criteria in solid tumors in locally advanced cervical cancer treated with chemoradiation

AU - Yoon, Jung Won

AU - Kim, Sunghoon

AU - Kim, Sang Wun

AU - Kim, YoungTae

AU - Kang, Won Jun

AU - Nam, Eun Ji

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Purpose To investigate whether the ratio of SUVs measured with 18F-FDG PET/CT between pretreatment and posttreatment has prognostic value in patients with locally advanced cervical cancer treated with primary chemoradiation therapy. Methods Cases of locally advanced cervical cancer (International Federation of Gynecology and Obstetrics stages IB1 to IVA) treated with a nonsurgical curative modality (172 cases including chemoradiation or radiation therapy) were reviewed. 18F-FDG PET/CT parameters, including SUVmax and SUVmean, were evaluated by 18F-FDG PET/CT performed prior to treatment and 6 weeks after the end of treatment. Metabolic response was evaluated according to the European Organization for Research and Treatment of Cancer guidelines and was compared with radiologic response measured according to the Response Evaluation Criteria In Solid Tumours (RECIST). Results In total, 142 patients receiving chemoradiation showed radiologic responses (median 56% decrease in maximal diameter), whereas 160 and 146 patients showed metabolic responses measured with SUVmax and SUVmean, respectively (73% decrease in SUVmax; 48% decrease in SUVmean). Radiologic response and metabolic response were significantly correlated for SUVmax and SUVmean (P = 0.0009; P = 0.0457, respectively). Kaplan-Meier analysis revealed significant differences in overall survival and progression-free survival between the responder and nonresponder groups, based on the European Organization for Research and Treatment of Cancer criteria (both P < 0.001), whereas no significant difference was found when using RECIST criteria (P = 0.058, P = 0.088, respectively). Conclusions 18F-FDG PET/CT parameters are good prognostic markers for the response of cervical cancer patients to concurrent chemoradiation therapy, as compared with the RECIST criteria.

AB - Purpose To investigate whether the ratio of SUVs measured with 18F-FDG PET/CT between pretreatment and posttreatment has prognostic value in patients with locally advanced cervical cancer treated with primary chemoradiation therapy. Methods Cases of locally advanced cervical cancer (International Federation of Gynecology and Obstetrics stages IB1 to IVA) treated with a nonsurgical curative modality (172 cases including chemoradiation or radiation therapy) were reviewed. 18F-FDG PET/CT parameters, including SUVmax and SUVmean, were evaluated by 18F-FDG PET/CT performed prior to treatment and 6 weeks after the end of treatment. Metabolic response was evaluated according to the European Organization for Research and Treatment of Cancer guidelines and was compared with radiologic response measured according to the Response Evaluation Criteria In Solid Tumours (RECIST). Results In total, 142 patients receiving chemoradiation showed radiologic responses (median 56% decrease in maximal diameter), whereas 160 and 146 patients showed metabolic responses measured with SUVmax and SUVmean, respectively (73% decrease in SUVmax; 48% decrease in SUVmean). Radiologic response and metabolic response were significantly correlated for SUVmax and SUVmean (P = 0.0009; P = 0.0457, respectively). Kaplan-Meier analysis revealed significant differences in overall survival and progression-free survival between the responder and nonresponder groups, based on the European Organization for Research and Treatment of Cancer criteria (both P < 0.001), whereas no significant difference was found when using RECIST criteria (P = 0.058, P = 0.088, respectively). Conclusions 18F-FDG PET/CT parameters are good prognostic markers for the response of cervical cancer patients to concurrent chemoradiation therapy, as compared with the RECIST criteria.

UR - http://www.scopus.com/inward/record.url?scp=84973303834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973303834&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000001269

DO - 10.1097/RLU.0000000000001269

M3 - Article

C2 - 27276204

AN - SCOPUS:84973303834

VL - 41

SP - 677

EP - 682

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 9

ER -